PRAX Praxis Precision Medicines,...

Nasdaq praxismedicines.com


$ 188.88 $ 27.28 (16.77 %)    

Friday, 17-Oct-2025 19:54:49 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 189.99
$ 178.90
$ 186.20 x 3
$ 189.16 x 1
$ 178.14 - $ 203.58
$ 26.70 - $ 205.89
4,431,426
na
4B
$ 0.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-04-2025 06-30-2025 10-Q
2 05-02-2025 03-31-2025 10-Q
3 02-28-2025 01-01-1970 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-05-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 02-07-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-03-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
18 05-11-2021 03-31-2021 10-Q
19 03-17-2021 12-31-2020 10-K
20 11-23-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 truist-securities-reiterates-buy-on-praxis-precision-medicine-raises-price-target-to-360

Truist Securities analyst Joon Lee reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target...

 guggenheim-maintains-buy-on-praxis-precision-medicine-raises-price-target-to-350

Guggenheim analyst Yatin Suneja maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target fro...

 chardan-capital-maintains-buy-on-praxis-precision-medicine-raises-price-target-to-330

Chardan Capital analyst Rudy Li maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target fro...

 deutsche-bank-maintains-buy-on-praxis-precision-medicine-raises-price-target-to-280

Deutsche Bank analyst David Hoang maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target f...

 praxis-precision-medicines-announces-proposed-public-offering-no-terms-disclosed

Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into th...

 needham-maintains-buy-on-praxis-precision-medicine-raises-price-target-to-250

Needham analyst Ami Fadia maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $80 ...

 praxis-precision-medicines-stock-doubles---heres-why

Praxis stock jumps after Phase 3 trials show ulixacaltamide significantly improves essential tremor symptoms and meets key effi...

 praxis-precision-medicines-ulixacaltamide-hcl-study-1-for-essential-tremor-met-primary-endpoint-all-key-secondary-endpoints-in-study-1-were-also-statistically-significant

Patients treated with ulixacaltamide in the parallel-group study (Study 1) showed a mean improvement from baseline in the Modif...

 praxis-precision-reports-phase-3-results-for-ulixacaltamide-in-essential-tremor

Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into th...

 jones-trading-initiates-coverage-on-praxis-precision-medicine-with-buy-rating-announces-price-target-of-83

Jones Trading analyst Justin Walsh initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and annou...

 praxis-precision-medicines-to-present-12-epilepsy-pipeline-updates-including-radiant-results-at-iec-2025-in-lisbon

Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION